Scaling Up Maternal Mental Healthcare by Increasing Access to Treatment (SUMMIT)

Summary

SUMMIT's (Scaling Up Maternal Mental health care by Increasing access to Treatment) overarching goal is to examine the scalability and patient-centered provision of brief, evidence-based psychological treatments for perinatal depression and anxiety (N=1226). Specifically, and through a multi-site, randomized, pragmatic trial, the trial examines whether a brief, behavioral activation (BA) treatment delivered via telemedicine is as effective as the same treatment delivered in person; and whether BA delivered by non-mental health providers (e.g., nurses), with appropriate training is as effective as when delivered by specialist providers (psychiatrists, psychologists and social workers) in reducing perinatal depressive and anxiety symptoms. The study will be conducted in Toronto, NorthShore University HealthSystem in Evanston and surrounding areas including Chicago, and North Carolina. The trial will also identify relevant underlying implementation processes and determine whether, and to what extent, these strategies work differentially for certain women over others.

Conditions

• Perinatal Depression

Interventions

BEHAVIORAL

Brief Behavioral Activation Treatment

A manualized 6-8 session BA treatment delivered individually to each participant.

Sponsors & Collaborators

• University of North Carolina, Chapel Hill

  collaborator OTHER

• Endeavor Health

  collaborator OTHER

• Women's College Hospital

  collaborator OTHER

• Unity Health Toronto

  collaborator OTHER

• Sunnybrook Health Sciences Centre

  collaborator OTHER

• University of Colorado, Boulder

  collaborator OTHER

• Harvard Medical School (HMS and HSDM)

  collaborator OTHER

• Patient-Centered Outcomes Research Institute

  collaborator OTHER

• Mount Sinai Hospital, Canada

  lead OTHER

Principal Investigators

• Daisy R Singla, PhD · Sinai Health System

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-01-06

Primary Completion

2024-02-26

Completion

2025-02-13

Countries

• United States
• Canada

Study Locations